AI-Powered RNA Trans-Splicing Therapeutics
Repairing disease-causing mutations at the RNA level — without altering genomic DNA
Sotirion Biosciences is developing a new class of precision medicines that repair disease-causing mutations at the RNA level without altering genomic DNA. By integrating artificial intelligence and RNA gene therapy, we accelerate the discovery of safer, more specific RNA medicines for cancer and genetic disorders. Central to our approach is the Sotirion Immune Repertoire Assay (SIRA) — a proprietary immune profiling technology that powers both our precision medicine strategy and companion diagnostic development.
Powered by SIRA, we profile each patient's immune repertoire to identify the right therapy for the right patient — targeting specific RNA splice variants with unprecedented precision.
Our SIRAFold™ platform integrates multi-omics data and structural modeling to rapidly identify and optimize RNA therapeutics across cancer and genetic disorders.
Harnessing the cell's own spliceosome machinery via SMaRT™ to correct defective transcripts — leaving the genome fully intact.
SIRA forms the foundation of our immune repertoire-based CompanionDx, enabling regulatory co-development of diagnostics alongside our lead RNA therapeutic program.
Three integrated innovations powering the future of RNA medicine
Spliceosome-Mediated RNA Trans-splicing
A breakthrough approach that leverages the cell's own natural machinery to repair defective RNA transcripts — offering a safer alternative to permanent genome editing.
Structural Integrated RNA Analysis & Folding
An AI-driven discovery engine that accelerates RNA therapeutic development by combining cutting-edge machine learning with deep molecular biology insights.
Immune Repertoire-Based Companion Diagnostic Platform
A precision companion diagnostic that profiles the immune repertoire to identify patients most likely to respond to SMaRT™ RNA trans-splicing therapy — bridging the gap between molecular targeting and patient-level response prediction.
Translating our platform science into actionable clinical tools
Immune Repertoire-Based MRD Detection for Blood Cancers
Sotirion's MRD Monitor leverages the Sotirion Immune Repertoire Assay (SIRA) to detect and track minimal residual disease in blood cancers with ultra-high sensitivity. By profiling the clonal architecture of T-cell and B-cell receptors, SIRA identifies residual malignant clones that evade conventional detection methods — enabling earlier intervention and more precise treatment decisions.
Peripheral blood or bone marrow sample is collected and immune cells are isolated for SIRA profiling.
SIRA sequences and characterizes the full T-cell and B-cell receptor repertoire at single-clone resolution.
AI-driven analysis identifies and tracks residual malignant clones — even at extremely low frequencies undetectable by standard methods.
Longitudinal MRD tracking informs treatment response, relapse risk, and therapy adjustments with precision.
Detects residual disease at frequencies as low as 1 in 106 cells — far beyond conventional flow cytometry or PCR-based MRD assays.
Optimized for hematologic malignancies including ALL, CLL, multiple myeloma, and other B- and T-cell lymphomas.
Serial sampling tracks clonal evolution over time, enabling real-time assessment of treatment efficacy and early detection of emerging resistance.
Designed for regulatory co-development as a companion diagnostic alongside Sotirion's SMaRT™ RNA trans-splicing therapies.
Interested in learning more? We'd love to hear from you.
20271 Goldenrod Ln
Germantown, MD 20876
Leveraging the NIH, NCI & Johns Hopkins ecosystem
Open to strategic collaborations
Research, clinical, and investment inquiries welcome
Actively seeking Series A investment